In this piece, we will look at the stocks Jim Cramer recently discussed.

Bernstein SocGen Group has revised its price target for Merck (NYSE:MRK) shares, bringing it down to $95 from the previous $110 while maintaining a Market Perform rating. Analyst Courtney Breen cited ...

Merck (MRK) is a leading global healthcare company recognized for its groundbreaking pharmaceutical products and vaccines.

They're all talking about HPV, or human papillomavirus. It's the most common sexually transmitted infection, but it's also ...

Here are seven attractively valued dividend stocks investors can bet on for the long term, according to Bank of America ...

Merck (NYSE: MRK) recently released its Q4 results, with revenues and earnings exceeding the street estimates.

to 4.6% in 2025 and 4.5% in 2026. A collapse in the Chinese housing market has undermined consumer confidence. Overall sales of Gardasil fell 17% to $1.55 billion in the final quarter of last year, ...

Executives pulled back on a 2030 sales target of $11 billion as demand for the HPV shot shrinks amid China market turmoil.